CR ESPI 25/2021 – Completion of second offering of shares in Aforti PLC private placement

The Management Board of Aforti Holding S.A., with its registered office in Warsaw (hereinafter: “Company”, “Issuer”), in reference to the current report ESPI 43/2020 of 22 July 2020 concerning the conclusion of an agreement with a broker that will lead to an indirect public listing of the Issuer’s subsidiary Aforti Exchange S.A. based in Warsaw on the Main Market of the London Stock Exchange, ESPI current report 47/2020 dated August 18, 2020 regarding the establishment of the Issuer’s subsidiary AFORTI PLC based in the United Kingdom, ESPI current report 50/2020 dated September 1, 2020, ESPI current report 75/2020 dated December 10, 2020 regarding the revaluation of Aforti Exchange S. A. and ESPI 76/2020 dated December 11, 2020 regarding share capital increase of Aforti PLC and current report ESPI 15/2021 dated March 1, 2021 , informs that today the Issuer has been informed by its subsidiary Aforti PLC, based in the United Kingdom, that on April 30, 2021 it completed the second round of offering new issue shares in a private placement.

The second round was attended by 14 individual investors, who subscribed for a total of 284 261 shares in Aforti PLC for GBP 224 942.69, confirming a valuation of the company after paid-in capital of approximately GBP 29.7 million. The subsidiary will commence a third round of offering its shares in a private placement from 4 May 2021.

The actions taken allow the continuation of activities carried out by a UK broker aimed at indirectly floating the Issuer’s subsidiary, Aforti Exchange S.A., headquartered in Warsaw, on the Main Market of the London Stock Exchange and raising up to €5 million in a private placement and another £4.5 million in an initial public offering on the LSE.

The offering of new issue shares in a private placement of Aforti PLC is related to the next stage of activities aimed at further implementation of the strategy of the Issuer’s Capital Group.

Legal basis: Article 17 paragraph 1 of the MAR – confidential information


More information